Prostate Cancer - Results from #27640

Active surveillance in prostate cancer: The need to standardize - Abstract June 21, 2011

Old issues and new perspectives on prostate cancer hormonal therapy: The molecular substratum - Abstract June 21, 2011

Patterns of information behavior and prostate cancer knowledge among African-American men - Abstract June 21, 2011

Effects of a 1-week inpatient course including information, physical activity, and group sessions for prostate cancer patients - Abstract June 21, 2011

Assessing software upgrades, plan properties and patient geometry using intensity modulated radiation therapy (IMRT) complexity metrics - Abstract June 21, 2011

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: Evaluation of cardiovascular events in a randomized trial June 21, 2011

A population-based study on the utilisation rate of primary radiotherapy for prostate cancer in 4 regions in the Netherlands, 1997-2008 - Abstract June 20, 2011

Pathology in prostate research: Optimizing the pathological data - Abstract June 20, 2011

Tumour markers in prostate cancer III: Biomarkers in urine - Abstract June 20, 2011

Updates on therapeutic targets and agents in castration-resistant prostate cancer - Abstract June 20, 2011

Active surveillance for favorable risk prostate cancer: Rationale, results, and vis a vis focal therapy role - Abstract June 20, 2011

TRP channels in prostate cancer: The good, the bad and the ugly? - Abstract June 20, 2011

Image-guided, adaptive radiotherapy of prostate cancer: Toward new standards of radiotherapy practice - Abstract June 20, 2011

Stereotactic body radiotherapy for prostate cancer: Current results of a phase II trial - Abstract June 20, 2011

Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: Potential of anti-IL-6 therapies - Abstract June 20, 2011

Editor's Commentary - Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression June 20, 2011

Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells - Abstract June 19, 2011

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer - Abstract June 17, 2011

The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies - Abstract June 17, 2011

Laparoendoscopic single site (LESS) radical prostatectomy: A review of the initial experience - Abstract June 17, 2011

Page 1383 of 1435